title: The effect of the cardioselective beta blocker celiprolol on pulmonary function in asthmatic patients.
abstract: The influence of single oral doses of 200 mg celiprolol, 100 mg atenolol, and 200 mg metoprolol on airway resistance (Raw) FEV1, VC, and MEF 50 was studied in a randomized double-blind crossover trial. Eighteen patients with hypertension and asthma, 14 men and 4 women, aged 43-75 years, took part. Pulmonary function tests were performed in the morning before treatment and 2 and 5 h after each treatment in the whole-body plethysmograph. The use of bronchodilators was not allowed during the 3 days. There was no significant change in airway resistance, FEV1, and MEF 50 after celiprolol and a slight increase of vital capacity at 2 h. After atenolol there was a decrease of FEV1 and MEF 50 at 5 h. Metoprolol caused an increase in resistance at 2 and 5 h and a fall in FEV1, VC, and MEF 50 at 2 and 5 h. Two patients required bronchodilator therapy after metoprolol and were excluded from evaluation. We conclude that celiprolol appears to be a safe drug in the treatment of asthmatic patients.
mesh_terms: D000319:Adrenergic beta-Antagonists / Q000009:adverse effects / Q000627:therapeutic use*; D000328:Adult; D000368:Aged; D000403:Airway Resistance / Q000187:drug effects; D001249:Asthma / Q000150:complications*; D017272:Celiprolol; D005260:Female; D005541:Forced Expiratory Volume; D006801:Humans; D006973:Hypertension / Q000150:complications / Q000188:drug therapy*; D008297:Male; D008448:Maximal Expiratory Flow Rate; D008875:Middle Aged; D011412:Propanolamines / Q000009:adverse effects / Q000627:therapeutic use*; D014797:Vital Capacity
chemical_list: D000319:Adrenergic beta-Antagonists; D011412:Propanolamines; D017272:Celiprolol